We are live on ! Find out more
LGM

Logos Global Management Portfolio holdings

AUM $2B
1-Year Est. Return 444.09%
This Fund
S&P 500
This Quarter Est. Return
-19.37%
1 Year Est. Return
+444.09%
3 Year Est. Return
+1,593.63%
5 Year Est. Return
+2,146.66%
10 Year Est. Return
–
AUM
$563M
AUM Growth
-$292M
Cap. Flow
-$116M
Cap. Flow %
-20.64%
Top 10 Hldgs %
61.97%
Holding
58
New
11
Increased
10
Reduced
6
Closed
19

Top Buys

Rank Stock Value
1
NUVL
Nuvalent
NUVL
+$39.1M
2
TEVA icon
Teva Pharmaceuticals
TEVA
+$30.4M
3
XENE icon
Xenon Pharmaceuticals
XENE
+$24.7M
4
KROS icon
Keros Therapeutics
KROS
+$23.2M
5
ETNB
89bio
ETNB
+$21.9M

Top Sells

Rank Stock Value
1
CYTK icon
Cytokinetics
CYTK
+$42.3M
2
VERA icon
Vera Therapeutics
VERA
+$37M
3
MRUS
Merus
MRUS
+$31.5M
4
INSM icon
Insmed
INSM
+$31.1M
5
NBIX icon
Neurocrine Biosciences
NBIX
+$27.3M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
IDYA icon
1
IDEAYA Biosciences
IDYA
$3.5B
$57.3M 10.19%
3,500,000
+500,000
+17% +$10.7M
RVMD icon
2
Revolution Medicines
RVMD
$40B
$56.6M 10.06%
1,600,000
+150,000
+10% +$6.09M
AKRO
3
DELISTED
Akero Therapeutics
AKRO
$48.6M 8.64%
1,200,000
+400,000
+50% +$17M
JANX icon
4
Janux Therapeutics
JANX
$945M
$44.5M 7.92%
1,650,000
+400,000
+32% +$15.1M
NUVL
5
DELISTED
Nuvalent
NUVL
$35.5M 6.3%
+500,000
New +$39.1M
TEVA icon
6
Teva Pharmaceuticals
TEVA
$36.2B
$26.1M 4.64%
+1,700,000
New +$30.4M
XENE icon
7
Xenon Pharmaceuticals
XENE
$6.35B
$21.8M 3.88%
+650,000
New +$24.7M
KROS icon
8
Keros Therapeutics
KROS
$207M
$20.4M 3.62%
+2,000,000
New +$23.2M
IRON icon
9
Disc Medicine
IRON
$2.87B
$19.6M 3.48%
394,342
+194,342
+97% +$10.8M
BNTX icon
10
BioNTech
BNTX
$23.2B
$18.2M 3.24%
200,000
-100,000
-33% -$11.2M
ETNB
11
DELISTED
89bio
ETNB
$18.2M 3.23%
+2,500,000
New +$21.9M
SLNO
12
DELISTED
Soleno Therapeutics
SLNO
$17.9M 3.18%
250,000
-100,000
-29% -$4.87M
ERAS icon
13
Erasca
ERAS
$6.63B
$17.8M 3.17%
13,000,000
+500,000
+4% +$858K
OCUL icon
14
Ocular Therapeutix
OCUL
$1.91B
$16.9M 3%
2,300,000
-1,200,000
-34% -$9.22M
DSGN icon
15
Design Therapeutics
DSGN
$748M
$16.3M 2.89%
4,217,627
– –
MLTX icon
16
MoonLake Immunotherapeutics
MLTX
$1.65B
$13.7M 2.43%
+350,000
New +$15.1M
GERN icon
17
Geron
GERN
$962M
$12.7M 2.26%
8,000,000
+6,000,000
+300% +$14.6M
OLMA icon
18
Olema Pharmaceuticals
OLMA
$1.07B
$12.1M 2.14%
3,208,875
– –
CRNX icon
19
Crinetics Pharmaceuticals
CRNX
$8.86B
$11.7M 2.09%
+350,000
New +$13.1M
RNAM
20
DELISTED
Avidity Biosciences
RNAM
$10.3M 1.84%
+350,000
New +$10.9M
MAZE
21
Maze Therapeutics
MAZE
$1.57B
$10.3M 1.83%
+936,914
New +$11.3M
ANNX icon
22
Annexon
ANNX
$867M
$7.72M 1.37%
4,000,000
+1,450,000
+57% +$4.83M
GPCR icon
23
Structure Therapeutics
GPCR
$3.53B
$7.36M 1.31%
425,000
-275,000
-39% -$6.74M
CMPS
24
Compass Pathways
CMPS
$1.54B
$5.72M 1.02%
+2,000,000
New +$7.68M
DYN icon
25
Dyne Therapeutics
DYN
$4.19B
$5.23M 0.93%
500,000
+50,000
+11% +$715K
1
2 3

Similar funds

MYAM
Meiji Yasuda Asset Management Tokyo, Japan $2B AUM 22.52% 1-Year Est. Return
RCM
Rivernorth Capital Management West Palm Beach, Florida $2B AUM 0.66% 1-Year Est. Return
LBC
Lowe Brockenbrough & Co Richmond, Virginia $2.01B AUM 22.05% 1-Year Est. Return
C
Consulta London, United Kingdom $2.01B AUM 16.82% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
BGM
Burkehill Global Management New York $2.02B AUM 85.32% 1-Year Est. Return
SC
Syon Capital San Francisco, California $1.99B AUM 22.67% 1-Year Est. Return
AF
Alerus Financial Grand Forks, North Dakota $2.02B AUM 26.03% 1-Year Est. Return

Logos Global Management's Q1 2025 Portfolio in Review

As of Q1 2025, Logos Global Management held 58 positions worth $563M, down 34% from $855M the previous quarter. Its ten largest holdings account for 62% of the portfolio.

Logos Global Management withdrew a net $116M in Q1 2025, closing 19 positions and reducing 6 holdings. Its most notable exit was Cytokinetics, an estimated $42.3M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, down from 100% a quarter earlier.

Against the trend, Logos Global Management opened a new position in Nuvalent worth $35.5M.

  • Logos Global Management's largest Q1 2025 buy was Nuvalent: 500,000 shares worth $35.5M.
  • Logos Global Management added most to Akero Therapeutics in Q1 2025, an estimated $17M increase.
  • Logos Global Management's biggest Q1 2025 reduction was BioNTech, cutting an estimated $11.2M.
  • Logos Global Management fully exited Cytokinetics in Q1 2025, selling an estimated $42.3M.
  • Logos Global Management's ten largest holdings make up 62% of its $563M portfolio in Q1 2025.
  • Logos Global Management opened 11 new positions and closed 19 in Q1 2025.
  • Logos Global Management's portfolio value fell 34% quarter-over-quarter to $563M.

Based on Logos Global Management's 13F filing for Q1 2025, filed 15 May 2025.